Whitehawk Therapeutics Inc 2025年度报告

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number 001-38560 WHITEHAWK THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days. YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflectthe correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any ofthe registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of commonstock on The NASDAQ Stock Market on June 30, 2025 was approximately $64.9 million.The number of shares of registrant’s common stock outstanding as of March 9, 2026 was 47,196,564. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed with the Securities and ExchangeCommission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated hereinby reference in Part III of this Annual Report on Form 10-K where indicated. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 6.[Reserved]117Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations118Item 7A.Quantitative and Qualitative Disclosures About Market Risk129Item 8.Financial Statements and Supplementary Data129Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure161Item 9A.Controls and Procedures161Item 9B.Other Information161Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspection161Part III Item 10.Directors, Executive Officers and Corporate Governance162Item 11.Executive Compensation162Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters162Item 13Certain Relationships and Related Transactions, and Director Independence162Item 14Principal Accountant Fees and Services162PART IV Item 15.Exhibits and Financial Statement Schedules163Item 16.Form of 10-K Summary165 Forward-Looking Statements This Annual Report on Form 10-K (“Annual Report”) contains express or implied forward-looking statements which are madepursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are based on our management’s belief andassumptions and on information currently available to our management. Although we believe that the expectations reflected inthese forward-looking statements are reasonable, these statements relate to future events or our future ope